Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon alpha 1b aerosol for pediatric RSV lower respiratory tract infection
ChiCTR2000040589Phase 3Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Dec 2019
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV), pulmonary infection, pneumonia and 1 more comparing Interferon alpha 1b aerosol with Placebo aerosol (2 arms). Primary endpoints: Efficacy of interferon alpha 1b aerosol and Safety of interferon alpha 1b aerosol. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
recombinant human interferon alpha-1b
03
Conditions
respiratory syncytial virus disease (RSV)pulmonary infectionpneumoniabronchiolitis
Beyond the preview
Go deeper on ChiCTR2000040589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040589.